Proteon Therapeutics is working to deliver a new future for patients and families affected by kidney and vascular diseases, where innovation drives health improvement and healthcare professionals have the tools they need to improve patient outcomes. Proteon is a late-stage biopharmaceutical company developing potentially transformative treatment options to address some of the most urgent needs in chronic kidney disease (CKD) and peripheral artery disease (PAD) with the goal of redefining how these diseases are treated. Proteonâs lead product candidate, vonapanitase, is a first-in-class recombinant human elastase designed to treat vessel injury that leads to blood vessel blockage and reduced blood flow. Proteon is evaluating vonapanitase in a Phase 3 trial in patients with CKD undergoing surgical creation of a radiocephalic arteriovenous fistula for hemodialysis and in a Phase 1 program in patients suffering from PAD.
Source
